Key result
Increased admission HbA1c levels were associated with a higher 1-year rate of major adverse cardiovascular events compared to lower HbA1c levels in patients with STEMI undergoing primary PCI.
Why the study?
Does admission HbA1c level predict in-hospital, short-, and long-term cardiovascular mortality and major adverse cardiovascular events in patients with STEMI undergoing primary PCI?
Observational (n=443)
No
Does admission HbA1c level predict in-hospital, short-, and long-term cardiovascular mortality and major adverse cardiovascular events in patients with STEMI undergoing primary PCI?
Answers are grounded in this paper and cite their sources.
Elevated admission HbA1c is associated with increased 1-year major adverse cardiovascular events in STEMI patients undergoing primary PCI, highlighting its prognostic value for risk stratification.
INTRODUCTION: Many studies have reported the diagnostic and prognostic value of haemoglobin A1c (HbA1c) levels in patients with acute coronary syndrome. However, the short- and long-term prognostic value of HbA1c level in patients with ST elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) is controversial. AIM: To investigate whether admission HbA1c level has a prognostic value for in-hospital, short-, and long-term cardiovascular (CV) mortality and major adverse cardiovascular events in patients with STEMI undergoing primary PCI. MATERIAL AND METHODS: This prospective study included 443 consecutive patients with STEMI who underwent primary PCI between September 2010 and July 2012. The patients were divided into three groups based on admission HbA1c levels: group I (HbA1c ≤ 5.6%), group II (HbA1c 5.7-6.4%), and group III (HbA1c ≥ 6.5%). The in-hospital, 1-month, and 1-year CV events of all 3 patient groups were followed up. RESULTS: A significant association was found between HbA1c level and 1-year primary clinical outcomes, including CV mortality, non-fatal reinfarction, and stroke (p = 0.037). In addition, age, Killip class > 1, and left ventricular ejection fraction were found to be independent predictors of long-term CV mortality in multivariate analysis (hazard ratios (95% confidence interval) 1.081 (1.020-1.146), 4.182 (1.171-14.935), and 0.832 (0.752-0.920); p = 0.009, p = 0.028, and p < 0.001, respectively). CONCLUSIONS: In this study, we demonstrated that increased admission HbA1c levels were associated with higher rates of major adverse CV events, including mortality, non-fatal reinfarction, and stroke, in patients with STEMI who underwent primary PCI.
No takes yet. Share an insight, caveat, or question.
Püşüroğlu et al. (2014) conducted an observational in ST-segment elevation myocardial infarction (STEMI) (n=443). Admission Haemoglobin A1c (HbA1c) ≥ 6.5% vs. Admission HbA1c ≤ 6.4% was evaluated on 1-year primary clinical outcomes (composite of cardiovascular mortality, non-fatal reinfarction, and stroke) (p=0.037). Increased admission HbA1c levels were associated with a higher 1-year rate of major adverse cardiovascular events compared to lower HbA1c levels in patients with STEMI undergoing primary PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: